Clinical Trials
104 trialsA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
GlaxoSmithKline
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
TroFuse-019
Merck Sharp & Dohme LLC
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pfizer
SUNRAY-01
Eli Lilly and Company
MK-7339-012
Merck Sharp & Dohme LLC
ALKAZAR
Nuvalent Inc.
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Krascendo 2
Hoffmann-La Roche
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ArriVent BioPharma, Inc.
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Genmab
REZILIENT4
Taiho Oncology, Inc.
PACIFIC-4
AstraZeneca
KANNON-2
Avistone Biotechnology Co., Ltd.
KontRASt-02
Novartis
Krascendo 1
Hoffmann-La Roche
Be6A Lung-02
Pfizer
LATIFY
AstraZeneca
ENSPIRIT
Achieve Life Sciences
MK-3475A-F84
Merck Sharp & Dohme LLC
VISUALIZE-2
Vergent Bioscience, Inc.
RASolve 301
Revolution Medicines, Inc.
AcceleRET-Lung
Hoffmann-La Roche
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme LLC
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Bintrafusp Alfa Program Rollover Study
EMD Serono
ADRIATIC
AstraZeneca
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.
Guangzhou JOYO Pharma Co., Ltd
VITAL
Sanofi
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
Qilu Pharmaceutical Co., Ltd.
Lotus
Formycon AG
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients
Prestige Biopharma Limited
KYLIN-3
Avistone Biotechnology Co., Ltd.
Bovine Reinforcement in Stomach, Colorectal and Lung Operation
Shanghai Cingularbio Co. Ltd
A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer
Cell>Point LLC
CONTERNO
Checkpoint Therapeutics, Inc.
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
ZEAL
Sanofi
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Samsung Bioepis Co., Ltd.
Effect of NUTRICAN to Improve Nutritional Status in Cancer Patients
Kalbe International Pte. Ltd
CheckMate870
Bristol-Myers Squibb
TRIIL
RDO Pharm.
MERMAID-2
AstraZeneca
REPLATINUM
EpicentRx, Inc.
ADELOS
AstraZeneca
CanStem43L
Sumitomo Pharma America, Inc.